Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITAN: Apalutamide plus ADT in mHSPC
NCT02489318Phase 3Active, not recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Sep 2020
- Modality
- Orthosteric Ligands
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Apalutamide plus ADT with Placebo plus ADT (2 arms). Primary endpoints: Radiographic Progression-free Survival at 35 months and Overall Survival at 57 months. Started Nov 2015; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02489318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489318.